Skip to content
Screener

Pacira BioSciences, Inc. PCRX iovera° — Total net product sales

Other product segments

EXPAREL
$143.27M+4.9%
ZILRETTA
$26.77M+14.7%
Bupivacaine liposome injectable suspension
$1.16M-55.5%

Similar metrics at other companies

Wabtec logo
WABProduct — Total Net Sales
$2.67B+19.9%
Carrier Global logo
CARRProduct — Total Net Sales
$5.63B+2.9%
Penguin Solutions logo
PENGProduct — Total Net Sales
$414.17M+60.1%
Eaton Corporation logo
ETNProducts — Total Net Sales
$2.08B+23.5%
Insight Enterprises logo
NSITProducts — Total Net Sales
$1.89B+13.2%
Mirum Pharmaceuticals, Inc. logo
MIRMProduct sales, net — Product sales, net
$176.24M+37.9%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$1.02B+1.3%
Enterprise value$1.29B+21.7%
P/E198.5×—
P/S1.4×0.0×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028871
Line itemThree Months Ended March 31, 20262025
Net product sales:
EXPAREL$143,274$136,529
ZILRETTA26,76723,338
iovera°6,1765,123
Bupivacaine liposome injectable suspension1,1592,604
Total net product sales$177,376$167,594

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Pacira BioSciences, Inc.'s iovera° — total net product sales?
Pacira BioSciences, Inc. (PCRX) reported iovera° — total net product sales of $6.18M in Q1 2026.
How has Pacira BioSciences, Inc.'s iovera° — total net product sales changed year-over-year?
Pacira BioSciences, Inc.'s iovera° — total net product sales increased by 20.6% year-over-year, from $5.12M to $6.18M.
What is the long-term trend for Pacira BioSciences, Inc.'s iovera° — total net product sales?
Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s iovera° — total net product sales has grown at a 10.6% compound annual growth rate (CAGR), from $16.16M to $24.18M.
What does iovera° — total net product sales mean?
This metric represents the total revenue generated from the sale of a specific medical device or therapeutic product line after accounting for returns, allowances, and discounts. It serves as a primary indicator of market adoption and commercial performance for the product segment. Tracking this figure allows investors to evaluate the growth trajectory and revenue contribution of the specific technology within the company's broader portfolio.

Ask your AI about Pacira BioSciences, Inc.'s iovera° — total net product sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude